Cognitive and Psychomotor Effects of Paroxetine and Sertraline on Healthy Elderly Volunteers

Furlan, Patricia; Kallan, Michael J.; Have, Thomas Ten; Pollock, Bruce G.; Katz, Ira R.; Lucki, Irwin

doi:10.1097/00019442-200111000-00012

Cited by 42 publications

(31 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Siepmann's et al's [2003] research with normal volunteers showed that sertraline does not have either a positive or a negative ef fect on cognition, and so argues against this possibility. Studies by Furlan's et al [2001] and Schmitt et al [2002] also suggested that sertraline improves depression-related cognition.…”

Section: Discussionmentioning

confidence: 96%

“…Tricyclic antidepressants, having very potent antihistaminic and anticholinergic effects, can interfere with cognitive and psychomotor functions [Riedel and van Praag, 1995]. Sertraline, however, has been shown to have no adverse effect on cognition in healthy volunteers [Furlan et al, 2001;Schmitt et al, 2002]. As our study shows an adverse effect on the executive functions of inhibition in depressed subjects, an improvement in these functions during sertraline treatment was probably related to the reduction in blood flow and cerebral glucose metabolism in the frontal regions in the depressive state [Baxter et al, 1989, Bench et al, 1992, Martinot et al, 1990 and to the increase in cerebral glucose metabolism in the frontal regions after 10 weeks of sertraline treatment [Buchsbaum et al, 1997].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of sertraline on depressive symptoms and attentional and executive functions in major depression

et al. 2005

View full text Add to dashboard Cite

Reports on the severity and reversibility of cognitive disturbances in major depression in the literature diverge due to methodological biases. The present study, using a precise methodology, examined attention and executive functions in 20 relatively young, depressed patients presenting a first or second episode of unipolar major depression without psychotic or melancholic characteristics and all being treated with the same psychopharmacological treatment (sertraline) to investigate the changes in potential attentional and executive loss during a subacute period of treatment of 7 weeks. We compared their performance with a group of 26 control subjects who were administered the same cognitive tests. This study confirmed psychomotor slowing associated with attentional and executive disturbance in adults with major depression. Conscious attentional interference for words with a negative emotional valence also was shown. After the first weeks of treatment, the effect of the antidepressant treatment with sertraline was accompanied by a beneficial effect on psychomotor slowing on attentional and executive functions.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Effects of sertraline on depressive symptoms and attentional and executive functions in major depression

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Given the important role of the basal ganglia circuits in motor functioning and the observed basal ganglia impairments in retarded depression, dopaminergic antidepressants such as sertraline are suggested to be responsible for motor improvement in depressed patients with psychomotor slowing. This is underpinned by a sertraline study in healthy elderly volunteers demonstrating increased finger-tapping speed -a pure motor test -after 2 weeks of treatment [33] . Moreover, monoamine oxidase inhibitors -that increase levels of dopamine, noradrenaline and serotonin -such as moclobemide have also been demonstrated to improve psychomotor performance in depressed patients [34][35][36] .…”

Section: Discussionmentioning

confidence: 99%

Psychomotor Changes in Major Depressive Disorder during Sertraline Treatment

Schrijvers

Maas

Pier³

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

Background: There is a relative scarcity of studies on major depressive disorder that use objective assessment methods to explore the psychomotor effects of antidepressants. Striatal dopaminergic disturbances are known to be involved in the pathogenesis of major depressive disorder that is associated with psychomotor retardation. Because of its additional dopaminergic mechanism, the psychomotor effects of the selective serotonin reuptake inhibitor sertraline merit further exploration. Methods: In 19 patients diagnosed with a current major depressive episode, clinical variables and graphic motor activity were assessed applying digitized figure copying tasks during a 6-week regimen of sertraline. Patients’ baseline and weekly psychomotor performance was compared with the outcomes of 22 healthy, unmedicated controls. Results: Patients’ psychomotor slowing had improved after 6 weeks on sertraline as reflected by reductions in initiation and movement times on the simple line and figure copying tasks and decreased initiation times for the complex figure copying task relative to their baseline outcomes. Conclusions: The current study found evidence pointing to potential beneficial effects of sertraline after a 6-week treatment period in the lower-order cognitive and motor components involved in the graphic motor performance of depressed patients. The present findings are discussed in terms of the mechanism of action of sertraline.

show abstract

“…Second generation antihistamines that have very limited effects on cognitive function in healthy subjects were also considered to have no CNS activity. Subjects taking CNS-active medications with mild or infrequent side effects on cognition or fatigue (e.g., SSRIs [21], beta-blockers [20], anticholinergics for bladder dysfunction [13,16]) or drugs with more consistent or more marked negative effects on cognitive function or fatigue (e.g., benzodiazepines, tricyclic antidepressants) were assigned to a second group.…”

Section: Medicationsmentioning

confidence: 99%

“…Many other drugs used by people with MS may negatively affect cognitive function as assessed by controlled trials in healthy control subjects, patient groups, or animals. This list includes tricyclic antidepressants, anticholinergics, first generation antihistamines, baclofen, beta-blockers, amantadine, selective serotonin reuptake inhibitors (SSRIs), and benzodiazepines [6][7][11][12][13][14][15][16][17][18][19][20][21]. On the other hand, methylphenidate and related drugs (modafinil) improve some cognitive functions in healthy subjects [11,[22][23].…”

Section: Introductionmentioning

confidence: 99%

Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity

Oken

Flegal

Zajdel

et al. 2006

JRRD

View full text Add to dashboard Cite

Abstract-To evaluate the potential effects of medications with central nervous system (CNS) activity on cognitive function and fatigue in multiple sclerosis (MS), we performed a retrospective analysis of medication use among 70 subjects with MS who were participating in a clinical trial for evaluation of the effects of yoga and exercise programs on cognition and fatigue. Among these MS subjects, 74% were taking at least one potentially CNS-active medication. These 70 subjects were divided into two groups: those taking at least one CNS-active medication (n = 52) and those not on any medications with potential CNS activity (n = 18). We compared assessments of cognitive function and fatigue using an analysis of covariance. MS subjects on CNS-active medication had greater impairment on measures of processing speed, sustained attention, and fatigue than those not on these medications. While these findings do not establish a causal relationship between medication use and cognitive impairment and fatigue, the data indicate that researchers need to control for use of CNS-active medications when conducting studies of cognitive impairment and fatigue in MS subjects.

show abstract

Cognitive and Psychomotor Effects of Paroxetine and Sertraline on Healthy Elderly Volunteers

Cited by 42 publications

References 19 publications

Effects of sertraline on depressive symptoms and attentional and executive functions in major depression

Effects of sertraline on depressive symptoms and attentional and executive functions in major depression

Psychomotor Changes in Major Depressive Disorder during Sertraline Treatment

Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity

Contact Info

Product

Resources

About